Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lentiviral vectors: progress and potential.

A M Lever1

  • 1University of Cambridge, Department of Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK. amll1@mole.bio.cam.ac.uk

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Superiority of 18F-FDG PET compared to 111In-labelled leucocyte scintigraphy in the evaluation of fever of unknown origin.

The Journal of infection·2012
Same author

The paraplegia patient; a nursing care study.

The American journal of nursing·2010
Same author

Bacteraemia and subsequent vertebral osteomyelitis: a retrospective review of 125 patients.

QJM : monthly journal of the Association of Physicians·2010
Same author

Comparative antimicrobial efficacy of multi-purpose hydrogel lens care solutions.

Contact lens & anterior eye : the journal of the British Contact Lens Association·2005
Same author

HIV: future and futuristic therapies.

Journal of HIV therapy·2002
Same author

RNA-based gene therapy for HIV infection.

HIV medicine·2001
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Lentiviral vectors show significant progress in gene therapy, enabling gene delivery and integration into target cells. Further research advances understanding of RNA processing and HIV molecular biology.

Area of Science:

  • Gene Therapy
  • Molecular Biology
  • Virology

Background:

  • Lentiviral vectors are gaining traction for in vivo gene therapy due to their gene integration capability.
  • Recent advancements have demonstrated successful gene delivery across diverse tissues.

Purpose of the Study:

  • To review key publications from the past 12 months in lentiviral vector research.
  • To highlight major achievements in lentiviral vector technology and applications.

Main Methods:

  • Review of scientific literature published within the last year.
  • Analysis of studies focusing on lentiviral vector production and gene transfer efficacy.

Main Results:

  • Demonstrated progress in gene delivery to various tissues via lentiviral vectors.

Related Experiment Videos

  • Expanded understanding of lentiviral vector production and utility in gene transfer.
  • New insights into RNA processing relevant to HIV molecular biology.

    • Conclusions:

    • Lentiviral vectors are a promising tool for gene therapy, with ongoing advancements.
    • Continued research is expected to lead to clinical applications in the near future.